Why the study?
The role of glutathione replenishment by N-acetylcysteine in limiting cardiac injury progression and TNF-alpha effects in hypertensive models was unclear.
Does N-acetylcysteine reduce cardiac injury and normalize TNF-alpha levels in a rat model of hypertension?
Does N-acetylcysteine reduce cardiac injury and normalize TNF-alpha levels in a rat model of hypertension?
In a rat model of hypertension, N-acetylcysteine supplementation replenishes cardiac glutathione, normalizes TNF-alpha levels, and attenuates left ventricular dysfunction and remodeling without affecting blood pressure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for NAC in hypertensive LV remodeling; leaves open translation to human therapy.
BACKGROUND: Studies in isolated cardiomyocytes showed that replenishment in cellular glutathione, achieved with the glutathione precursor N-acetylcysteine (NAC), abrogated deleterious effects of tumor necrosis factor-alpha (TNF-alpha). METHODS AND RESULTS: We examined the ability of NAC to limit the progression of cardiac injury in the rat model of hypertension, induced by the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) (50 mg/kg per day SC) and high-salt diet (HS) (8% NaCl). Four-week HS/L-NAME administration induced hypertension (193+/-8 versus 122+/-4 mm Hg for low-salt diet [LS] group) and left ventricular (LV) dysfunction, revealed by echocardiography and characterized by decreased LV shortening fraction (38+/-2% versus 49+/-4% for LS group; P<0.05) and decreased LV posterior wall thickening (49+/-3% versus 70+/-4% for LS group; P<0.05). LV dysfunction worsened further after 6-week HS/L-NAME administration. Importantly, increase in serum TNF-alpha level was strongly correlated with shortening fraction decrease and cardiac glutathione depletion. NAC (75 mg/d) was given as a therapeutic treatment in a subgroup of HS/L-NAME animals during weeks 5 and 6 of HS/L-NAME administration. NAC treatment, which replenished cardiac glutathione, had no effect on hypertension but reduced LV remodeling and dysfunction, normalized serum TNF-alpha level, and limited activation of matrix metalloproteinases -2 and -9 and collagen deposition in LV tissues. CONCLUSIONS: These findings suggest that glutathione status determines the adverse effects of TNF-alpha in cardiac failure and that TNF-alpha antagonism may be achieved by glutathione supplementation.
No takes yet. Share an insight, caveat, or question.
Bourraindeloup et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: